» Articles » PMID: 29174471

Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer

Overview
Publisher Elsevier
Specialties Oncology
Urology
Date 2017 Nov 28
PMID 29174471
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Partial nephrectomy (PN) for clinical stage T3 tumors is controversial. Radical nephrectomy (RN) has been associated with a greater rate of chronic kidney disease, an increased risk of cardiovascular disease, and increased mortality compared with PN. We present our long-term 2-center experience with PN for stage pT3a tumors and compare the oncologic outcomes with those of similar patients treated with RN.

Materials And Methods: We reviewed the data from all patients who had undergone nephrectomy for renal cell carcinoma from 1987 to 2015 in 2 medical centers. The study included 134 patients with pathologic stage T3a tumors, of whom 48 and 86 underwent PN and RN, respectively. We compared the 2 groups (PN and RN) using univariate and multivariate analyses.

Results: The tumors of all patients with pathologic stage T3a who had undergone PN had been pathologically upstaged from clinical stage T1 or T2. Univariate and multivariate analyses revealed tumor size was significantly different statistically between the study groups (median, 7.0 cm in RN group vs. 4.0 cm in PN group; P < .001). Surgery type was not a predictor of local recurrence (P = .978), metastatic progression (P = .972), death from renal cancer (P = .626), or death from all causes (P = .974) at the 5-year follow-up point.

Conclusion: The results of the present study have shown similar oncologic outcomes between 48 patients with stage pT3a renal cancer who underwent PN and 86 patients who underwent RN. Although PN was not performed on clinical T3a tumors, our findings suggest that PN can also be considered for these tumors and, thus, avoid the long-term complications of RN. However, strict follow-up protocols are mandatory.

Citing Articles

Nephrectomies in Saudi Arabia: A Comprehensive Analysis of Outcomes from a High-Volume Minimally Invasive Surgery Center.

Alasker A, Alnafisah T, Shafqat A, Sabbah B, Alaswad M, Alghafees M J Kidney Cancer VHL. 2024; 11(3):1-12.

PMID: 39045259 PMC: 11261389. DOI: 10.15586/jkcvhl.v11i3.332.


Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Xing Z, Xu H, Ai K, Deng H, Hong Y, Deng P Ann Surg Oncol. 2024; 31(5):3531-3543.

PMID: 38329657 DOI: 10.1245/s10434-024-14958-x.


Preserving Renal Function without Compromising Oncological Outcomes: A Comparative Study of Partial and Total Nephrectomies in T3 Stage Renal Cell Carcinoma.

Alasker A, Alnafisah T, Alghafees M, Shafqat A, Sabbah B, Alhaider A J Kidney Cancer VHL. 2024; 10(4):28-32.

PMID: 38162464 PMC: 10755761. DOI: 10.15586/jkcvhl.v10i4.290.


A novel DNA methylation signature revealed GDF6 and RCC1 as potential prognostic biomarkers correlated with cell proliferation in clear cell renal cell carcinoma.

Xu Z, Wu Y, Zhao G, Jin B, Jiang P Mol Biol Rep. 2023; 51(1):16.

PMID: 38087057 DOI: 10.1007/s11033-023-09003-1.


Robotic Partial Radical Nephrectomy for Clinical T3a Tumors: A Narrative Review.

Stout T, Gellhaus P, Tracy C, Steinberg R J Endourol. 2023; 37(9):978-985.

PMID: 37358403 PMC: 10623454. DOI: 10.1089/end.2023.0173.